Trial register facet
Reported trial records — page 4
644 records with the status reported.
Showing 0 records on this page
Records
644 documents · page 4 of 27
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| MARITIDE-PH2-OBESITY | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 592 | 2024 | Low |
| MARITIDE-PH2-T2D | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Low |
| STEP-HFpEF-DM-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-4-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-OSA-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
| SURMOUNT-OSA-2-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| FLOW-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SUMMIT-BIOMARKERprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| MARITIDE-PH2-OBESITY-HEPATIC-IMPprogramme record | Maridebart cafraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MARITIDE-PH2-T2D-REGIONAL-JPprogramme record | Maridebart cafraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| DREAMS-2-RENAL-IMPprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ELDERLYprogramme record | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-MASH-PKprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SYNERGY-NASH-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| PETRE-PH1B-ADHERENCEprogramme record | Petrelintide | Phase 1 | Reported | Observational | — | 2024 | Very low |
| REIMAGINE-1-RENAL-IMPprogramme record | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-4-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| SURMOUNT-OSA-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| FLOW-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SUMMIT-ADHERENCEprogramme record | Tirzepatide | Phase 3 | Reported | Observational | — | 2024 | Very low |
| MARITIDE-PH2-T2D-BODY-COMPprogramme record | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| DREAMS-2-PKprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-OBESITY-OLEprogramme record | Survodutide | Phase 2 | Reported | Single-arm open-label | — | 2024 | Very low |
| SURVO-PH2-MASH-RENAL-IMPprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
page 4 of 27